Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 551.45 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 1.09 mg (equivalent: topotecan, qty 1 mg) - injection, concentrated - excipient ingredients: tartaric acid; hydrochloric acid; sodium hydroxide; water for injections - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 4.346 mg (equivalent: topotecan, qty 4 mg) - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; tartaric acid - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - aciclovir, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - aciclovir intravenous infusion is indicated for the purpose of:,1. promoting resolution of acute clinical manifestations of mucocutaneous herpes simplex virus infections in immunocompromised patients.,2. treatment of severe first episode primary or non-primary genital herpes in immune competent patients.,3. treatment of acute manifestations of varicella zoster virus infection in immunocompromised patients.,4. treatment of shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease. benefits can be expected in patients with rash duration shorter than 72 hours. the use of the intravenous infusion may be warranted in only a small subgroup of immune competent patients with shingles.,5. treatment of herpes simplex encephalitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - arsenic trioxide, quantity: 10 mg - injection, concentrated - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide - for the induction of remission and consolidation in patients with acute promyelocytic leukaemia (apl) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.,for the induction of remission and consolidation in patients with previously untreated acute promyelocytic leukaemia (apl) in combination with all-trans retinoic acid (atra) and/or chemotherapy and whose apl is characterised by the presence of the t(15:17) translocation or pml/rar-alpha gene expression.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bortezomib, quantity: 1 mg - injection, powder for - excipient ingredients: mannitol - bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - bortezomib, quantity: 3.5 mg - injection, powder for - excipient ingredients: mannitol - bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease.,bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - epirubicin hydrochloride, quantity: 200 mg - injection, concentrated - excipient ingredients: water for injections; sodium chloride; hydrochloric acid - epirubicin has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of breast cancer, gastric cancer, ovarian cancer, small cell lung cancer, lymphoma (non-hodgkin's lymphoma), advanced/ metastatic soft tissue sarcoma, superficial bladder cancer (tis; ta). in bladder cancer, epirubicin is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grades 2 and 3).